Dr Reddys Laboratories (RDY) Cash from Operations (2009 - 2026)

Dr Reddys Laboratories has reported Cash from Operations for 17 years, with the latest figure at -$9.8 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 105.73% year-over-year to -$9.8 million in Q2 2026; TTM through Jun 2026 was $450.9 million, a 13.73% decrease from a year earlier, with the FY2026 full-year figure at $607.0 million, up 11.38% from the prior year.
• Cash from Operations was -$9.8 million for Q2 2026 at Dr Reddys Laboratories, down from $178.6 million in the prior quarter.
• The five-year high for Cash from Operations was $283.3 million in Q4 2022, with the low at -$9.8 million in Q2 2026.
• Average Cash from Operations over 5 years is $139.2 million, with a median of $129.1 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Cash from Operations soared 284.56% in 2022, then plunged 105.73% in 2026.
• Over 5 years, Cash from Operations stood at $283.3 million in 2022, then tumbled by 79.92% to $56.9 million in 2023, then surged by 95.51% to $111.2 million in 2024, then soared by 60.54% to $178.6 million in 2025, then sank by 105.48% to -$9.8 million in 2026.
• The last three Cash from Operations figures came in at -$9.8 million (Q2 2026), $178.6 million (Q3 2025), and $170.9 million (Q2 2025), per Business Quant data.